Mayo Clinic (Rochester)
Rochester, MN
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
CA088-1005
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 1
- Has results
Accepting patients
MMSET Inhibitor
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- H3K36me2
- Phase 1
- Has results
- T Cell Engager (TCE)
- Bispecific Antibody
- CD3
- BCMA
- Randomization
- Maintenance
- High Risk
- Phase 2
Accepting patients
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Monoclonal Antibody
- CD38
- Phase 3
Accepting patients
Dasatinib & Quercetin with CAR-T Cell Therapy
DART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy
- CAR T Cell
- Tyrosine Kinase (TK) Inhibitor
- Antioxidant
- Phase 2
Accepting patients
Venetoclax Plus Lenalidomide
Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) in t(11;14) Multiple Myeloma
- BCL-2 Inhibitor
- Quadruplet Therapy
- Phase 1
Accepting patients
Iberdomide Combination Therapy
Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma
- CELMoD
- Phase 1/2
Accepting patients
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Monoclonal Antibody
- CD38
- Randomization
- Maintenance
- Phase 3
Accepting patients
SAR446523
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma
- Monoclonal Antibody
- GPRC5D
- Phase 1
2 hidden based on your filters.Show All